Case Report: Immune Checkpoint Blockade Plus Interferon-Γ Add-On Antifungal Therapy in the Treatment of Refractory Covid-Associated Pulmonary Aspergillosis and Cerebral Mucormycosis

Invasive fungal diseases (IFD) still cause substantial morbidity and mortality, and new therapeutic approaches are urgently needed. Recent data suggest a benefit of checkpoint inhibitors (ICI). We report the case of a diabetic patient with refractory IFD following a SARSCoV-2 infection treated by ICI and interferon-gamma associated with antifungal treatment.

• Publication year

  2022

• Venue

  Frontiers in Immunology

• Publication date

  2022-06-01

• Fields of study

  Medicine, Environmental Science

• Identifiers
  DOI 10.3389/fimmu.2022.900522PMID 35720319PMCID 9199385
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effective Anti–SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders

  2022cited by this paper
• Immune Checkpoint Blockade for Aspergillosis and Mucormycosis Coinfection

  2021cited by this paper
• PD-1 blockade improves survival and fungal clearance, induces pro-inflammatory lung cytokines and synergizes with caspofungin in a pulmonary aspergillosis model.

  2020cited by this paper
• Defining ‘T cell exhaustion’

  2019cited by this paper
• Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy

  2019cited by this paper
• Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab

  2019cited by this paper
• Immune checkpoint blockade in infectious diseases

  2017cited by this paper
• Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy

  2017cited by this paper
• Anti–PD-1 Antibody Treatment Promotes Clearance of Persistent Cryptococcal Lung Infection in Mice

  2017cited by this paper
• Nivolumab plus interferon-γ in the treatment of intractable mucormycosis.

  2017cited by this paper
• T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

  2017cited by this paper
• Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease.

  2016cited by this paper
• T cells from patients with Candida sepsis display a suppressive immunophenotype

  2015influential reference
• Molecular and cellular insights into T cell exhaustion

  2015cited by this paper
• Overcoming T cell exhaustion in infection and cancer.

  2015cited by this paper
• Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series

  2014cited by this paper
• Characterization of Specific Immune Responses to Different Aspergillus Antigens during the Course of Invasive Aspergillosis in Hematologic Patients

  2013cited by this paper
• Blockade ofthe negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis

  2013influential reference
• T cell exhaustion

  2011cited by this paper
• Therapeutic PD-L1 and LAG-3 blockade rapidly clears established blood-stage Plasmodium infection

  2011cited by this paper
• Exogenous Interferon‐γ Immunotherapy for Invasive Fungal Infections in Kidney Transplant Patients

  2010influential reference
• Case Series

  2010cited by this paper
• Enhancing SIV-Specific Immunity In Vivo by PD-1 Blockade

  2008cited by this paper
• The PD-1/PD-L costimulatory pathway critically affects host resistance to the pathogenic fungus Histoplasma capsulatum

  2008cited by this paper
• Immunomodulation with interferon‐gamma and colony‐stimulating factors for refractory fungal infections in patients with leukemia

  2005influential reference

• Exhausted T cell phenotypes in disseminated coccidioidomycosis

  2026cites this paper
• Emergence, function, and therapeutic strategies to target the PD-1/PD-L1 immune checkpoint during pathogenic fungal infections

  2025cites this paper
• Invasive mould infection in children - advances made or obstacles remaining?

  2025cites this paper
• Invasive Aspergillosis Caused by Cryptic Species in Transplant Recipients: A Review.

  2025cites this paper
• Case Report: Immune checkpoint inhibitor exhibits dual benefits for a refractory lymphoma patient with disseminated mucormycosis

  2025cites this paper
• Early adjunct anti-PD-L1 immunotherapy improves outcomes and restores infection-induced immune paralysis in mice with invasive pulmonary mucormycosis

  2025influential citation
• Immune Phenotypes in Patients With Invasive Mould Infection Support the Use of PD‐1 Inhibition as Potential Treatment Option

  2025cites this paper
• Diagnosis and management of invasive fungal infections due to non-Aspergillus moulds

  2025cites this paper
• Antifungal immunity: advances in PRR recognition, adaptive responses, and immune-based therapies

  2025cites this paper
• CAF to the Rescue! Potential and Challenges of Combination Antifungal Therapy for Reducing Morbidity and Mortality in Hospitalized Patients With Serious Fungal Infections

  2024cites this paper
• Mixed Aspergillosis and Mucormycosis Infections in Patients with COVID-19: Case Series and Literature Review

  2024cites this paper
• Pharmacological management of invasive mold infections in solid organ transplant recipients

  2024cites this paper
• Invasive Mykosen – Innovative Therapien

  2024cites this paper
• Invasive Mykosen – Innovative Therapien

  2024cites this paper
• Epidemiology, pathogenesis, clinical characteristics, and treatment of mucormycosis: a review

  2024cites this paper
• Combined antifungal therapy with immunostimulation for refractory cutaneous and peritoneal mucormycosis caused by Rhizopus microsporus.

  2024cites this paper
• What Is New in Pulmonary Mucormycosis?

  2023cites this paper
• New anticancer therapeutics impact fungal pathobiology, infection dynamics, and outcome

  2023cites this paper
• Prediction of pulmonary aspergillosis in patients with ventilator-associated pneumonia

  2023cites this paper
• Novel Approaches in the Management of Mucormycosis

  2023cites this paper
• Treatment of Invasive Aspergillosis: How It’s Going, Where It’s Heading

  2023cites this paper
• Exploiting antifungal immunity in the clinical context.

  2023cites this paper
• Successful Multimodal Therapy with Intracerebral Liposomal Amphotericin B and Systemic High-Dose Isavuconazole in Proven Disseminated Aspergillosis

  2023cites this paper
• Checkpoint inhibitors as immunotherapy for fungal infections: Promises, challenges, and unanswered questions

  2022cites this paper
• Dexamethasone/tocilizumab

  2022cites this paper